Decoding Chronic Kidney Disease: How Routine Data Can Improve Outcomes
"Learn how analyzing existing health data can lead to better prevention and treatment strategies for chronic kidney disease."
Chronic diseases pose a significant and growing challenge to healthcare systems worldwide. Effectively managing these conditions requires innovative strategies that can streamline care, target resources efficiently, and improve patient outcomes. Traditionally, research for conditions such as cardiovascular disease has led the way in developing prognostic tools and targeted interventions.
Now, researchers are exploring how similar approaches can be applied to other chronic conditions, with a focus on Chronic Kidney Disease (CKD). CKD represents a particularly compelling case study, as it often precedes the need for renal replacement therapy (RRT), such as dialysis or kidney transplantation. By identifying patients at risk and intervening early, healthcare providers can potentially delay disease progression and improve overall quality of life.
A recent study delved into the potential of using routinely collected clinical data to understand and manage CKD more effectively. By analyzing data on kidney function, RRT initiation, and mortality, researchers aimed to identify patterns and risk factors associated with CKD progression. This approach offers a cost-effective way to gain insights into the disease and inform the development of targeted interventions.
CKD Prevalence and Kidney Failure in the United States
According to NIDDK’s summary of the CDC’s 2023 report, CKD affects 14% of women and 12% of men in the United States. The reported prevalence is about 20% among non-Hispanic Black adults and approximately 12% among non-Hispanic White adults. The United States Renal Data System’s 2023 Annual Data Report counted more than 808,000 people living with end-stage kidney disease (ESKD): 68% were on dialysis and 32% had a kidney transplant.
Guidelines, Risk Estimation, and Detection
The supplied materials identify the ADD-CKD Study (Awareness, Detection and Drug Therapy in Type-2 Diabetes and Chronic Kidney Disease) as research on primary-care detection of CKD in adults with type 2 diabetes. A recommendation in the supplied guideline material advises using an externally validated risk equation to estimate absolute kidney-failure risk in people with CKD stages G3–G5. The materials provided here do not specify the limitations of these approaches.
How the Definition of CKD Evolved
A 2019 review describes CKD as having been redefined in the new millennium as persistent kidney-related alterations lasting at least three months. The definition encompasses changes in kidney morphology or function, or in blood or urine composition. It can include conditions such as kidney scarring after acute pyelonephritis or having a single kidney, even when kidney function is normal; an earlier account notes that the label replaced the term “renal insufficiency.”
Unlocking Insights: How Routine Data Can Transform CKD Management
The study, led by Marks, Fluck, Prescott, MacLeod, Smith, and Black, utilized data from the Aberdeen Applied Renal Research Collaboration (ARRC) at the University of Aberdeen and NHS Grampian in Scotland. The researchers focused on identifying a cohort of patients with CKD using routine clinical data, including serum creatinine levels (a measure of kidney function), RRT initiation records, and death registrations. This allowed them to track the progression of the disease and identify factors associated with mortality over a six-year period.
- Age-Related RRT Initiation: RRT initiation rates decreased with age, from 14.3 per 100 person-years among those aged 15–25 to just 0.7 per 100 person-years among those aged 75–85 at baseline.
- Age-Related Mortality: Mortality rates increased with age, ranging from 1.9 per 100 person-years for those aged 15–45 to 33.8 per 100 person-years for those over 85 at baseline.
- Increased Mortality Risk: Compared to the general population, individuals with CKD faced a significantly elevated mortality risk, with a 19-fold increase for those aged 15-45 and a 2-fold increase for those over 85.
New Directions in CKD Research
A June 2026 Lancet Series paper describes CKD as a complex, multisystem condition that often occurs alongside cardiovascular disease, diabetes, obesity, and infection. It outlines therapeutic advances aimed at shared inflammatory, metabolic, and fibrotic pathways, including SGLT2 inhibitors and non-steroidal therapies. A September 2026 Nature Reviews Nephrology item reports that frailty is highly prevalent in people with CKD and is associated with increased mortality, hospitalization, disability, and poorer quality of life.
Limits of Routine-Data Identification
A cross-sectional study of an ontological approach to identifying CKD cases from routine primary-care data warns that inaccurate coding may limit the method’s specificity. Separately, a systematic review of administrative database coding for kidney disease reports that missing data in primary studies limited some of the analyses it could perform. These findings point to coding accuracy and data completeness as constraints on the evidence described by these sources.
Dialysis and Conservative Kidney Management
A 2018 paper describes conservative care as a reasonable alternative to dialysis for some older people with advanced CKD, while noting that comparisons are scarce and generally focus on survival. A January 2026 article highlights that frailty, multimorbidity, and functional decline in older adults with ESKD can limit dialysis’s survival benefit and challenge the conventional approach to renal replacement therapy. The materials summarize these considerations but do not establish a single preferred option for every patient.
The Path Forward: Using Data to Drive Better CKD Care
This study demonstrates the potential of leveraging routinely collected data to gain valuable insights into CKD and improve patient outcomes. By identifying risk factors and patterns associated with disease progression, healthcare providers can develop targeted interventions to delay the need for RRT and reduce mortality. Further research is needed to explore the optimal strategies for utilizing routine data to inform clinical decision-making and improve the lives of individuals living with CKD.
Emerging Tools and Priorities
A 2023 perspective reports that CKD affects over 850 million people globally and argues that preventing its development and progression is urgent. It points to new biomarkers, imaging methods, and artificial intelligence among the tools and interventions emerging for CKD diagnosis and management. Separately, updated U.S. estimates published in July 2026 indicate that overall national CKD burden has remained stable, while an increasing proportion is associated with diabetes.
Patient Experience and Health-System Pressures
The Hannah Oldfield case study explores a patient’s experience during admission to a nephrology ward. It identifies hypertension, diabetes, and acute kidney injury as causes of CKD, and says progression could be slowed with medication to reduce blood pressure and glucose levels, alongside dietary and lifestyle changes. A 2022 early-detection resource describes CKD burden as increasing most rapidly in low- and middle-income countries, where rising demand for expensive kidney replacement therapies poses a major health-system challenge.